VectraplexECG with VectraplexAMI technology is a novel system for streamlining performance of noninvasive cardiac monitoring and detection of acute myocardial infarction. The manufacturer VectraCor has sought and recently obtained regulatory device approval in both the United States and Europe.
The device and software algorithm is designed to replace the equipment and testing needed to obtain a 12 lead ECG, continuous cardiac monitoring, and serial laboratory tests for serum cardiac markers such as troponin if an acute myocardial infarction is suspected.
VectraplexECG machine
According to device inventor Dr. Dave Schreck, this is accomplished through the placement of 5 leads (both arms and legs and V2) and sophisticated software that analyzes the degree of electrical multipolarity of the cardiac electrical force, with a greater presence of multipolarity indicating more likely presence of pathology.
The manufacturer reports a negative predictive value of 98% and a sensitivity of 93%, making it a possible consideration to be used in the emergency room for patient reporting with chest pain, although with indications for use in the operating room and intensive care units.
The post VectraplexECG Technology Receives FDA and CE Mark Clearance appeared first on InsideSurgery Medical Information Blog.
